Live
PharmaVoiceProtein degraders gain speed as Arvinas scores landmark approvalEndpoints NewsWindward Bio gets $165M to take China-derived drug into Phase 3 asthma trialLabiotechNeedle-free diabetes care: 6 devices that painlessly monitor blood sugarThermo FisherThermo Fisher Introduces Gibco CTS DynaXS Single Use Bioreactor For Scalable Cell Therapy Manufacturing - BioPharma APACFierceBiotechCelcuity’s gedatolisib beats Novartis’ Piqray in phase 3 breast cancer studyFierceBiotechUCB inks $2B Candid buyout to join Gilead in autoimmune fieldIlluminaIllumina Partners with Florida State University Lab for Rare Disease Genome Sequencing - Clinical Lab ProductsBioPharma DiveUCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseasesBioPharma DiveWhat is your AI drug repurposing strategy missing?FierceBiotech‘Real momentum’ or ‘completely absurd’? How Trump’s support has shaken up psychedelicsCytiva (Google News)Rockwell Automation and Cytiva join hands to accelerate digital transformation for biopharma companies - BioSpectrum AsiaCytiva (Google News)Rockwell Automation and Cytiva Introduce Figurate SCADA: Addressing Digital Fragmentation in Biopharma Manufacturing - ARCweb.com
BioPharma Dive Jan 22, 2026

Investors load Corxel with $287M for a ‘differentiated’ obesity pill

Investors load Corxel with $287M for a ‘differentiated’ obesity pill

Original
Body unavailable. Use the original source.